BioMarin Pharmaceutical | BMRN - Cash And Equivalent


BioMarin Pharmaceutical reported $1.25B in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Agios Pharmaceuticals USD 92.71M 11.84M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Bayer EUR 5.9B 1.34B Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Incyte USD 2.93B 508.08M Sep/2025
Insmed USD 334.76M 949.56M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Moderna USD 1.13B 147M Sep/2025
Neurocrine Biosciences USD 340.2M 76.2M Sep/2025
PTC Therapeutics USD 672.62M 344.77M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
United Therapeutics USD 1.34B 253M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025